胰高血糖素样肽1激动剂用于减重:是否增加非糖尿病患者初次全髋关节置换术的并发症?
基于保险理赔数据库的回顾性研究,纳入2010年1月1日至2022年1月1日接受初次全髋关节置换术的非糖尿病患者,将使用胰高血糖素样肽1(GLP-1)激动剂者(n=5,345)与未使用者(n=5,345)按1:1倾向评分匹配。结果显示GLP-1激动剂使用与急性失血性贫血、术后输血及90天内急诊就诊风险降低相关,未增加深静脉血栓、肺栓塞、死亡、手术并发症及2年全因翻修风险。
要点
- GLP-1激动剂组急性失血性贫血风险低于对照组(OR 0.57;95%CI 0.34-0.96)。
- GLP-1激动剂组术后输血风险低于对照组(OR 0.53;95%CI 0.36-0.78)。
- 两组深静脉血栓、肺栓塞、死亡、手术并发症及2年全因翻修风险无显著差异(P>0.05)。
核心结论
- 在仅因减重使用GLP-1激动剂的非糖尿病患者中,使用GLP-1激动剂似乎不增加全髋关节置换术后内科和外科并发症的发生风险。
研究设计与样本
- 回顾性查询2010年1月1日至2022年1月1日保险理赔数据库,识别接受初次全髋关节置换术且使用GLP-1激动剂的患者(n=839,715)。
- 术时使用GLP-1治疗者(n=5,345)按年龄、性别、Elixhauser共病指数及其组成部分与未使用GLP-1激动剂者(n=5,345)进行1:1倾向评分匹配,排除糖尿病患者。
- 评估90天结局包括内科并发症、再入院和再手术率,并检查2年随访时全因翻修和植入物相关并发症发生率,使用逻辑回归生成比值比(OR)。
主要发现
- GLP-1激动剂组急性失血性贫血风险低于对照组(OR 0.57;95%CI 0.34-0.96)。
- GLP-1激动剂组术后输血风险低于对照组(OR 0.53;95%CI 0.36-0.78)。
- GLP-1激动剂组术后90天内急诊就诊风险低于对照组(OR 0.81;95%CI 0.69-0.92)。
- 两组深静脉血栓、肺栓塞、死亡、卒中、心肌梗死、急性肾损伤和脓毒症风险相当(P>0.05)。
- 两组吸入性肺炎发生率相似(OR 1.17;95%CI 0.62-2.19),且GLP-1治疗未增加90天和2年手术并发症风险,包括假体周围关节感染、不稳、骨折、松动或全因翻修(P>0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glucagon-like peptide 1 (GLP-1) agonists are an effective medication for glycemic control and weight loss. These effects may reduce complications in diabetic patients undergoing total hip arthroplasty (THA). However, there remains a paucity of data on the impact of GLP-1 medications in nondiabetic patients using the medication solely for weight reduction. There is concern that rapid weight loss associated with GLP-1 agonists may lead to malnutrition and increase the risk of postoperative complications in patients undergoing THA. METHODS: A retrospective query was performed from January 1, 2010, to January 1, 2022, using an insurance claims database to identify patients undergoing primary THA on GLP-1 agonists (n = 839,715). Patients on GLP-1 therapy (n = 5,345) at the time of surgery were propensity score-matched 1:1 to controls who were not on GLP-1 agonists (n = 5,345) based on age, sex, the Elixhauser Comorbidity Index, and its components. Patients who had diabetes mellitus were excluded. The 90-day outcomes were evaluated, including medical complications, readmission, and reoperation rates. We also examined the incidence of all-cause revision and implant-related complications at a 2-year follow-up. Odds ratios (ORs) were generated using logistic regression analyses. RESULTS: Patients who were on GLP-1 agonist medications were less likely to develop acute blood loss anemia (OR: 0.57; 95% confidence interval [CI]: 0.34 to 0.96) and require postoperative transfusion (OR: 0.53; 95% CI: 0.36 to 0.78) or visit the emergency department within 90 days of surgery (OR: 0.81; 95% CI: 0.69 to 0.92) when compared to patients who did not have GLP-1 therapy. Patients were at comparable risk of deep venous thrombosis, pulmonary embolism, mortality, stroke, myocardial infarction, acute kidney injury, and sepsis regardless of GLP-1 status (P > 0.05). Notably, the rate of aspiration pneumonia was similar between groups (OR: 1.17; 95% CI: 0.62 to 2.19). Also, GLP-1 therapy did not put patients at higher risk of surgical complications, including periprosthetic joint infection, instability, fracture, loosening, or all-cause revision, at 90 days and two years (P > 0.05). CONCLUSIONS: Use of a GLP-1 agonist does not appear to increase the odds of postoperative medical and surgical complications after THA in nondiabetic patients taking GLP-1 medications for weight loss alone.
引用
- Verhey JT, Austin RP, Tarabichi S, et al. GLP-1 Agonists for Weight Loss: Do They Increase Complications in Non-diabetic Patients Undergoing Primary Total Hip Arthroplasty? J Arthroplasty. 2025. PMID: 40081604. doi:10.1016/j.arth.2025.03.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。